Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr. Adam Wilkinson

Dr. Adam Wilkinson

Adam Wilkinson

MBiochem PhD

Associate Professor of Stem Cell Biology

  • KKLF Intermediate Research Fellow


After completing his undergraduate degree at the University of Oxford, Adam Wilkinson undertook PhD training at the University of Cambridge with Prof. Bertie Gottgens. He then moved to Japan and California to perform postdoctoral training with Prof. Hiromitsu Nakauchi at the University of Tokyo and Stanford University. In 2020, he moved into an Instructor position at the Stanford Institute for Stem Cell Biology and Regenerative Medicine with funding from the US National Institutes of Health (NIH), the Leukemia and Lymphoma Society, and Edward P. Evans Foundation. Most recently, he joined the MRC Molecular Haematology Unit (MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford) as a Group Leader in 2021, supported by funding from the Kay Kendall Leukemia Fund.

Research Summary

The Wilkinson group aims to better understand the biology and translational applications of haematopoietic stem cells (HSCs). HSCs are an adult stem cell population that support life-long blood and immune system function and are also used clinically in stem cell (or bone marrow) transplantation therapies. In particular, the group is interested in developing and applying new ex vivo culture technologies to study healthy and malignant HSCs. The overall goal of this research is to improve treatment options for patients suffering from haematological diseases.